« Previous
Next »
The Journal of Urology
Volume 180, Issue 5
, Pages
1986-1992
, November 2008
A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America
To access this article, please choose from the options below
Supported by Ferring Pharmaceuticals A/S.
Study received institutional review board approval.
PII: S0022-5347(08)01836-3
doi: 10.1016/j.juro.2008.07.033
© 2008 American Urological Association. Published by Elsevier Inc. All rights reserved.
« Previous
Next »
The Journal of Urology
Volume 180, Issue 5
, Pages
1986-1992
, November 2008

